๐๐ข๐ฏ๐๐ซ๐จ๐ฑ๐๐๐๐ง ๐.๐ ๐ฆ๐ ๐๐ฐ๐ข๐๐ ๐๐๐ข๐ฅ๐ฒ: ๐๐๐ฌ๐๐ฎ๐ฅ๐๐ซ-๐๐ซ๐จ๐ญ๐๐๐ญ๐ข๐จ๐ง ๐๐จ๐ฌ๐
Rivaroxaban 2.5 mg twice daily, when combined with low-dose aspirin (75โ100 mg once daily), is a vascular-protection regimen used in selected patients with:
โ๐๐ก๐ซ๐จ๐ง๐ข๐ ๐๐จ๐ซ๐จ๐ง๐๐ซ๐ฒ ๐ฌ๐ฒ๐ง๐๐ซ๐จ๐ฆ๐ (๐๐๐/๐๐๐)
โ๐๐ฒ๐ฆ๐ฉ๐ญ๐จ๐ฆ๐๐ญ๐ข๐ ๐ฉ๐๐ซ๐ข๐ฉ๐ก๐๐ซ๐๐ฅ ๐๐ซ๐ญ๐๐ซ๐ฒ ๐๐ข๐ฌ๐๐๐ฌ๐ (๐๐๐/)
โ๐๐๐ ๐๐จ๐ฅ๐ฅ๐จ๐ฐ๐ข๐ง๐ ๐ฅ๐จ๐ฐ๐๐ซ-๐๐ฑ๐ญ๐ซ๐๐ฆ๐ข๐ญ๐ฒ ๐ซ๐๐ฏ๐๐ฌ๐๐ฎ๐ฅ๐๐ซ๐ข๐ณ๐๐ญ๐ข๐จ๐ง
This strategy is often referred to as dual-pathway inhibition, combining low-dose factor Xa inhibition with antiplatelet therapy to reduce major cardiovascular and limb events.
The 2.5 mg twice-daily dose is not a full therapeutic anticoagulant dose and should not be used as the anticoagulant regimen for:
Atrial fibrillation โ stroke/systemic embolism prevention requires the appropriate AF anticoagulant dose.
Acute DVT or PE โ treatment requires the full therapeutic VTE regimen.
1September 5, 2026 135 2
